文献速递湿疹皮炎与荨麻疹

乌帕替尼剂量递增与递减治疗中重度特应性皮炎的IIIb/IV期研究

Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up).
PubMed 文献 · Br J Dermatol · 2025-01-01

这项随机盲法多中心IIIb/IV期研究纳入461例中重度特应性皮炎成人患者,先接受乌帕替尼15mg或30mg治疗12周,之后根据是否达到EASI 90进行剂量递增或递减。第24周时,递增至30mg组48.1%达到EASI 90,递减至15mg组68.5%维持EASI 90,安全性与此前已知特征一致,未发现新信号。

要点

  • 第12周未达EASI 90者递增至30mg后,第24周48.1%达到EASI 90。
  • 第12周达EASI 90的30mg组递减至15mg后,第24周68.5%维持EASI 90。
  • 安全性与此前已知乌帕替尼特征一致,未报告恶性肿瘤、静脉血栓事件或死亡。

核心结论

  • 基于第12周是否达到EASI 90进行乌帕替尼剂量递增或递减,两种策略均支持第24周达到和维持EASI 90。
  • 整体安全性与此前已知乌帕替尼安全性特征一致,未发现新安全性信号。

研究设计与样本

  • 随机盲法治疗达标多中心IIIb/IV期研究,共461例中重度特应性皮炎成人患者随机1:1接受乌帕替尼15mg(n=229)或30mg(n=232)每日一次,双盲期12周。
  • 第12周未达EASI 90的15mg组递增至30mg(UPA15/30),达EASI 90者继续15mg(UPA15/15);未达EASI 90的30mg组继续30mg(UPA30/30),达EASI 90者递减至15mg(UPA30/15),再治疗12周。
  • 主要疗效终点为第24周EASI 90达标率,结果按实际观测描述性报告,并评估安全性。

主要发现

  • 第24周,剂量递增组(UPA15/30)48.1%(n=64/133;95%CI 39.6-56.6)达到EASI 90。
  • 第24周,剂量递减组(UPA30/15)68.5%(n=89/130;95%CI 60.5-76.4)维持EASI 90。
  • 继续初始剂量组中,UPA30/30有29.3%(n=24/82;95%CI 19.4-39.1)达到EASI 90,UPA15/15有74.6%(n=53/71;95%CI 64.5-84.8)维持EASI 90。
  • 第24周,UPA15/30和UPA30/15组分别有32.5%(n=27/83;95%CI 22.5-42.6)和38.0%(n=38/100;95%CI 28.5-47.5)达到最严重瘙痒数字评定量表评分0或1(WP-NRS 0/1)。
  • 第24周,UPA15/30和UPA30/15组分别有20.7%(n=17/82;95%CI 12.0-29.5)和35.0%(n=35/100;95%CI 25.7-44.3)达到EASI 90且WP-NRS 0/1。

关键数值与推荐

  • 主要疗效终点为第24周EASI 90达标率。
  • 第24周治疗中出现的不良事件发生率:UPA15/15为43.1%(n=31/72),UPA15/30为54.2%(n=78/144),UPA30/30为61.5%(n=56/91),UPA30/15为48.9%(n=65/133)。
  • 未报告恶性肿瘤、经 adjudication 的静脉血栓栓塞事件或死亡。

临床怎么用

  • 对乌帕替尼15mg治疗12周未达EASI 90的中重度特应性皮炎患者,可考虑递增至30mg以争取第24周达到EASI 90。
  • 对乌帕替尼30mg治疗12周已达EASI 90的患者,可考虑递减至15mg维持治疗,第24周多数可维持EASI 90。
  • 剂量调整策略需结合瘙痒改善(WP-NRS)和安全性个体化评估。

局限性

  • 结果按实际观测描述性报告,未报告正式统计检验。
  • 摘要未报告盲法维持、长期安全性或生活质量的具体数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pivotal clinical trials have assessed the efficacy and safety of fixed-dose upadacitinib 15 mg (UPA15) and 30 mg (UPA30) once daily in atopic dermatitis (AD). OBJECTIVES: To assess the efficacy and safety of dose escalation to UPA30 and dose reduction to UPA15 based on a clinical response [90% reduction in Eczema Area and Severity Index (EASI 90)] after 12 weeks of treatment in adults with moderate-to-severe AD enrolled in a randomized blinded treat-to-target multicentre phase IIIb/IV study. METHODS: A total of 461 patients were randomized in a 1 : 1 ratio to receive oral doses of UPA15 (n = 229) or UPA30 (n = 232) once daily during the 12-week double-blinded period. At week 12, patients on UPA15 not achieving EASI 90 were dose escalated to UPA30 (UPA15/30); patients achieving ≥ EASI 90 continued on UPA15 (UPA15/15). Patients on UPA30 not achieving EASI 90 at week 12 continued on UPA30 (UPA30/30); patients achieving ≥ EASI 90 received a reduced dose of UPA15 (UPA30/15) for 12 additional weeks. The primary efficacy endpoint was EASI 90 achievement at week 24. Results were reported descriptively as observed. Safety outcomes were assessed. RESULTS: At week 24, of patients who received dose escalation (UPA15/30), 48.1% [n = 64/133; 95% confidence interval (CI) 39.6-56.6] achieved EASI 90; of patients who received a dose reduction (UPA30/15), 68.5% (n = 89/130; 95% CI 60.5-76.4) maintained EASI 90. Of patients who continued on their initial dose, 29.3% (n = 24/82; 95% CI 19.4-39.1) on UPA30/30 achieved EASI 90 and 74.6% (n = 53/71; 95% CI 64.5-84.8) on UPA15/15 maintained EASI 90. At week 24, 32.5% (n = 27/83; 95% CI 22.5-42.6) and 38.0% (n = 38/100; 95% CI 28.5-47.5) of patients on UPA15/30 and UPA30/15, respectively, achieved a worst pruritus numerical rating scale score of 0 or 1 (WP-NRS 0/1), and 20.7% (n = 17/82; 95% CI 12.0-29.5) and 35.0% (n = 35/100; 95% CI 25.7-44.3), respectively, achieved combined EASI 90 and WP-NRS 0/1. At week 24, treatment emergent adverse events were reported in 43.1% (n = 31/72; UPA15/15), 54.2% (n = 78/144; UPA15/30), 61.5% (n = 56/91; UPA30/30) and 48.9% (n = 65/133; UPA30/15) of patients. No malignancies, adjudicated venous thromboembolic events or deaths were reported. CONCLUSIONS: Treatment of moderate-to-severe AD with UPA15 or UPA30, with dose escalation or dose reduction based on achievement of the optimal treatment target of EASI 90 at week 12, demonstrated that both approaches support the achievement and maintenance of EASI 90 at week 24. Overall safety findings were consistent with the known UPA safety profile, with no new safety signals identified. Eczema, also known as atopic dermatitis (‘AD’), is a skin disease that causes itchiness, redness and scaling of the skin. Previous studies have tested how effective and safe a drug called upadacitinib (‘UPA’ for short) is in treating AD. The doses of UPA that have been tested are 15 mg and 30 mg. This study looked at how effective and safe adjusting the dose of UPA in adults with moderate-to-severe AD was over a period of 24 weeks. To do this, patients were divided into two groups. Patients in one group took the lower dose of UPA (15 mg). The other group took the higher dose (30 mg). All patients took their allocated dose of UPA every day for 12 weeks. If a patient’s skin did not improve by 90% when taking the initial dose, they were either given the higher dose or they stayed on the same higher dose. If a patient’s skin improved considerably, they either stayed on the lower dose or were moved from the higher dose to the lower dose. After 24 weeks, approximately half of the patients with AD who switched from the lower dose to the higher dose of UPA had 90% improvement in their skin. Most patients who switched from the higher dose to the lower dose of UPA kept their good skin. Across both dose adjustment groups, patients also experienced improvements in their quality of life. The safety findings were consistent with what is already known about UPA. No new safety concerns were found. The results support dosing strategies for the approved doses of UPA in managing moderate-to-severe AD. Dose adjustments helped to achieve and maintain treatment goals.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Gooderham M, Torres T, Imafuku S, et al. Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up). Br J Dermatol. 2025. PMID: 40581082. doi:10.1093/bjd/ljaf236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。